4th Quarter - Report

BROWN RUDNICK LLP for EXELA HOLDINGS, LLC

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Implementation of P.L. 112-144 (FDA Safety and Innovation Act)

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen. Stabenow (05-07)
HENRY W MENN CoS, Sen. Bob Graham (01 - 04)

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.